EKSPO FARMA LTD established as a medical health care products sales company stand in 2007. Its first international activity was attending the FİME 2007 Medical Trade Fair – Miami in the USA .

After many years internal and external trade experinces, our goal  is producing equivalent high technology medical devices and health care products which have been importing in Turkey for many years. Increasing sales, expanding our business and customer satifaction are our objectives.

Ekspo Farma is the World’s First Integrated Urology Company to be Certified by the European Union’s Medical Device Regulation.

The MDR certification replaced the former EU Medical Device Directive (MDD) on 26th May 2021. It includes a more robust legislative framework that enforces a higher standard of public health and patient safety.


R & D and Clinical Trials

For the development of its products, Ekspo Farma has moved its headqauter at İnönü University at 2019 and opened R & D Center.

In the case of the development of our medical device called ‘’ Injectable Gel for treatments of Vesicoureteral Reflux (VUR) and Stress Urinary Incontinence (SUI)’’, we have been proceeding our facilities under ISO 13485 standarts for Design and Development and Manufacturing Management of the medical device and CE certificated it on July 2020. For the development of the medical device, we have permission from Turkish Ministry of Health Ethics Committee Decision for performing clinical trials and completed clinical trials.


Injectable Gel for treatment of Vesicoureteral Reflux (VUR) and Stress Urinary Incontinence (SUI).

Injectable Gel is contained in a single use disposable 1 ml syringe for treatments of Vesicoureteral Reflux (VUR) and Stress Urinary Incontinence (SUI). The gel is presented with registered with 3 trade Marks – DEXSUI®, HYADEX® and DEXVUR®

The 1 ml syringe is equipped with a tip cap, plunger and plunger rod. The syringe is terminally steam sterilized. The gel  is a sterile, viscous gel containing Dextranomer- microspheres range in size between 80-250 microns and non-animal based cross-linked hyaluronic acid. It is a biocompatible reaction material used in the treatment of vesicoureteral reflux (VUR) and Stress Urinary Incontinence (SUI). Cross-linked hyaluronic acid acts as a carrier for basic Dextranomer-microparticles. Dextranomer-microparticles form volume on the connective tissue in the injected region.

The gel is injected submucosally in the urinary bladder in close proximity to the ureteral orifice. The injection of the gel creates increased tissue bulk thereby providing coaptation of the distal ureter during filling and contraction of the bladder. The dextranomer microspheres are gradually surrounded by host connective tissue.


E-catalogs of our products
Vesicoureteral Reflux (VUR) Treatment

Stress Urinary Incontinence (SUI) Treatment


News from our company

If you would like to get more information, please contact us;


+90 530 181 79 08